Why MEDP beats the market
Up 177% over five years while the S&P 500 rose 58%; up 4% in the past year.
- Its profit per share went from $3.84 to $15.28; revenue grew 22.3% a year.
MEDP's Quality Score fell 2 points on Fri, Nov 20, to 9. Its week-by-week trend stopped pointing up (2 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 177% over five years while the S&P 500 rose 58%; up 4% in the past year.
| The chart | Stronger than 87% of stocks |
| Latest filing | 10-Q, Oct 22 |
After its last 4 reports it closed -6.3% on average, higher 1 of 4 times.
Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. MEDP scores 9 today, against a median of 14 over its last 20 recorded sessions.
MEDP is #31 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 31 |
Sales over four quarters against a year before: MEDP +20%, ICLR +0.4%, IQV +8.8%.
Expected to report Mon Feb 8, after the close (in 79 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $716.0M, 9% more than a year ago; a profit of $4.84 a share, from $3.86.
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Oncology | $230M | $209M | $193M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 22)
| Measure | Figure |
|---|---|
| Diluted earnings per share (GAAP) | $17.97 to $18.32 |
Sales grew 22% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 4.8% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 21, 2026 | -0.8% | -1.3% | +4.6% |
| Jul 22, 2026 | +22.5% | +14.7% | +10.8% |
| Apr 22, 2026 | -26.2% | -22.6% | -18.7% |
Sales grew every year from 2018 to 2025, to $2.5B. It made a profit in each of the eight years.
RSI 37.9, MACD below signal, below its 50-day, above its 200-day. Not scored.
8 insiders sold $230M across 35 filings in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: MEDP is under 0.1% of SCHG and under 0.1% of VTI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
“We compete primarily against other full-service CROs as well as services provided by in-house research and development (R&D) departments of biopharmaceutical companies.”
MEDP scores 9 today, which Breakaway calls Average. It is #31 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 177% over five years while the S&P 500 rose 58%; up 4% in the past year. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
MEDP scores 9 today, which Breakaway calls Average (6 to 10). That is #31 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MEDP's 9.
8 insiders sold $230M across 35 filings in the last 6 months. No open-market buys on record. The newest is Stephen P. Ewald, General Counsel & Corp. Secy., who sold $859K on Oct 29. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.